Abstract Number: 0396 • ACR Convergence 2026
Performance of the DUET ultrasound enthesitis score in a real-world setting as a diagnostic tool in early PsA: An external validation prospective cohort study (PREDICT Study)
Background/Purpose: Diagnostic delay remains a major challenge in psoriatic arthritis (PsA), in part due to the lack of reliable tools to distinguish PsA from other…Abstract Number: 1448 • ACR Convergence 2026
Improving recognition of multisystem complications in rheumatoid arthritis: Can generative AI bridge the clinical gap?
Background/Purpose: Recognition of multisystem complications in rheumatoid arthritis (RA) is often incomplete in routine care, particularly for complex, uncommon, or rare diseases (CURDs). We evaluated…Abstract Number: 1686 • ACR Convergence 2026
Agreement Between Commercial Artificial Intelligence and Expert Capillaroscopist in Nailfold Capillary Density Assessment: A Two-Center Validation Study
Background/Purpose: Nailfold videocapillaroscopy (NVC) is essential in systemic sclerosis (SSc) evaluation. Capillary density (capillaries/mm) is a key quantitative parameter for clinical trials. AI-based platforms have…Abstract Number: 1719 • ACR Convergence 2026
Development and Validation of an Interactive Chatbot as a Screening Tool for Inflammatory Arthritis : A Single-Centre Pilot Study
Background/Purpose: Inflammatory arthritis (IA) poses a significant diagnostic challenge at the primary care level, causing delayed institution of effective pharmacotherapy. A population-based screening strategy for…Abstract Number: 1960 • ACR Convergence 2026
Amplification of the Th17/IL-17 Pathway Activation Marks the Transition from Very Early Systemic Sclerosis (VEDOSS) to Established Systemic Sclerosis: A Multi-Omics Analysis
Background/Purpose: Systemic sclerosis (SSc) carries the highest mortality among rheumatic diseases, underscoring the need to identify immunological drivers before irreversible organ damage occurs. The Very…Abstract Number: 2260 • ACR Convergence 2026
LupusBench: A Mixed-Format Benchmark for Evaluating Large Language Models in Systemic Lupus Erythematosus – A Pilot Study
Background/Purpose: Medical large language model benchmarks are essential for standardizing task performance, scoring procedures, and safety assessments. Broad medical benchmarks, including MultiMedQA/Med-PaLM, HealthBench, MedHELM, and…Abstract Number: 2454 • ACR Convergence 2026
Clinical Accuracy, Safety and Completeness of Large Language Models for Pregnancy, Family Planning and Lactation Counseling in Inflammatory Rheumatic Diseases: An Expert-Rated Comparative Study
Background/Purpose: The rate of integration and use of Large Language Models (LLMs) in the diagnosis and treatment of inflammatory rheumatic diseases (iRMD) has shown a…Abstract Number: 2661 • ACR Convergence 2026
From Assessment to Action: Physician Global Assessment and Treatment Escalation in Inflammatory Arthritis
Background/Purpose: Physician Global Assessment (PhGA) is widely used to assess disease activity in inflammatory arthritis and often guides treatment decisions. However, the PhGA threshold associated…Abstract Number: 2718 • ACR Convergence 2026
Cost-effectiveness Analysis of Screening for Antimalarial-induced Cardiomyopathy in Systemic Lupus Erythematosus Patients on Hydroxychloroquine
Background/Purpose: Hydroxychloroquine (HCQ) is prescribed in almost all patients with systemic lupus erythematosus (SLE). Antimalarial-induced cardiomyopathy (AMIC) is a rare but life-threatening complication of long-term…Abstract Number: 2933 • ACR Convergence 2026
Large-Scale Plasma Proteomics Identifies Orosomucoid 1 as a Circulating Predictor of Difficult-to-Treat Rheumatoid Arthritis
Background/Purpose: Despite biologic (b) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs), approximately 10.9% of rheumatoid arthritis (RA)1 patients meet the EULAR definition of difficult-to-treat…Abstract Number: 0449 • ACR Convergence 2025
Consistency of CDAI Low-Disease Activity (LDA) Outcomes with Time in a Large US Registry: Association With Patient-Reported Clinical Outcomes and Measures of Quality of Life
Background/Purpose: Low disease activity has been identified as a treatment goal for the treatment of RA. A singlecenter RA registry (BRASS) reported a difference in…Abstract Number: 1050 • ACR Convergence 2025
Bridging the Gap: A Mixed-Methods Study to Enhance Integration of HCQ-SAFE, A Shared Decision-Making Tool for Hydroxychloroquine Use, in Routine Lupus Care
Background/Purpose: Hydroxychloroquine (HCQ) is a key therapy for lupus (or SLE). Yet, challenged to weigh benefits vs. harms, ~80% of patients self-discontinue HCQ. Shared decision-making…Abstract Number: 1051 • ACR Convergence 2025
Mitigating Hydroxychloroquine (HCQ) Nonadherence by Clarifying Misbeliefs Using a Shared Decision-Making Tool (HCQ-SAFE©) Across Two Different Rheumatology Centers
Background/Purpose: Hydroxychloroquine (HCQ) prolongs disease-free and damage-free survival in lupus (SLE). Yet, ~80% of patients stop taking HCQ resulting in poor outcomes including early mortality.…Abstract Number: 1052 • ACR Convergence 2025
“Prednisone… A Necessary Evil…” Developing an Evidence-Based Benefits vs. Harms Shared Decision-Making Tool (PRED-SAFE) to Support Decisions Around Chronic Prednisone Use
Background/Purpose: Guidelines recommend limiting chronic prednisone use ( >5 mg/d for >3-6 mos.) given higher risks of fractures, infections, and damage. Yet, patients struggle to…Abstract Number: 1186 • ACR Convergence 2025
Increased Adoption of IL-1 Pathway Inhibition and the Steroid-sparing Paradigm Shift: Temporal Trends in Recurrent Pericarditis Treatment From the RESONANCE Patient Registry
Background/Purpose: Recurrent pericarditis (RP) is a chronic autoinflammatory disease mediated by IL-1 that requires long-term treatment. While the 2015 European Society of Cardiology Guidelines position…
ACR Meeting Abstracts